DDAVP (NEEDS NO REFRIGERATION) Drug Patent Profile

When do Ddavp (needs No Refrigeration) patents expire, and what generic alternatives are available?

Ddavp (needs No Refrigeration) is a drug marketed by Ferring Pharms Inc and is included in one NDA.

The generic ingredient in DDAVP (NEEDS NO REFRIGERATION) is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ddavp (needs No Refrigeration)

A generic version of DDAVP (NEEDS NO REFRIGERATION) was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for DDAVP (NEEDS NO REFRIGERATION)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	28
Patent Applications:	237
DailyMed Link:	DDAVP (NEEDS NO REFRIGERATION) at DailyMed

Recent Clinical Trials for DDAVP (NEEDS NO REFRIGERATION)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	NA
Second Affiliated Hospital of Wenzhou Medical University	PHASE1
Kashiv BioSciences, LLC	PHASE1

See all DDAVP (NEEDS NO REFRIGERATION) clinical trials

US Patents and Regulatory Information for DDAVP (NEEDS NO REFRIGERATION)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996		DISCN	Yes	No

Expired US Patents for DDAVP (NEEDS NO REFRIGERATION)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996
Ferring Pharms Inc	DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	017922-003	Aug 7, 1996

International Patents for DDAVP (NEEDS NO REFRIGERATION)

See the table below for patents covering DDAVP (NEEDS NO REFRIGERATION) around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	3034405
Czech Republic	9503391
France	1540536	Procédé de préparation d'un polypeptide analogue de la vasopressine
Greece	3036936
China	1040648
Japan	H09502425
China	1125952

Supplementary Protection Certificates for DDAVP (NEEDS NO REFRIGERATION)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622	C02712622/01	Switzerland		PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
2712622	201740002	Slovenia		PRODUCT NAME: DESMOPRESSINE OR ITS ACETATE SALT; NATIONAL AUTHORISATION NUMBER: H/16/02212/001-008; DATE OF NATIONAL AUTHORISATION: 20160818; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE497271,BE497280; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20160504; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101

DDAVP (desmopressin) – Market Dynamics and Financial Trajectory for “Needs No Refrigeration” Formulation

Last updated: April 23, 2026

What is DDAVP and where does “no refrigeration” fit?

DDAVP is the brand name for desmopressin, a synthetic analog of vasopressin used in diabetes insipidus, nocturnal enuresis, and related conditions. “Needs no refrigeration” applies to select marketed presentations that can be stored at controlled room conditions rather than conventional refrigeration requirements for some other liquid/insulin-style products.

Practical market meaning: for DDAVP, storage requirements affect patient adherence, pharmacy handling, distribution cost, and tender eligibility (especially in regions with cold-chain limitations). Those factors translate into measurable channel behavior: fewer dispensing failures, lower risk of temperature excursions, and smoother outpatient logistics.

Which DDAVP product configurations drive channel economics?

Across major markets, desmopressin for DDAVP is sold in multiple dosage forms. The “no refrigeration” claim is most relevant to certain retail-ready presentations (often oral melt/tablet or room-stable formats, depending on country approvals and labeling). In market practice, channel economics hinge on three variables:

• Storage class: room-stable vs refrigerated
• Dosing frequency: once- or twice-daily impacts adherence and refill cadence
• Payer status: whether reimbursed under chronic-use formularies vs specialty cost share

How does “no refrigeration” change buyer behavior and distribution efficiency?

Room-stable requirements influence procurement and fulfillment in three direct ways:

1. Fewer cold-chain bottlenecks
   Cold chain adds cost and failure points. A room-stable DDAVP presentation reduces temperature excursion risk during last-mile distribution.

2. Lower logistics friction
   Pharmacies and wholesalers handle room-stable SKUs with less segregation, less packaging spend, and lower operational complexity.

3. Lower adherence friction
   Patient behavior improves when storage is easy. Desmopressin therapy is long-term in many indications, so adherence and refill continuity are financially material.

Net market dynamic: “no refrigeration” converts cold-chain savings and operational reliability into repeat demand through fewer dispensing disruptions and smoother chronic refills.

---

What are the demand drivers for desmopressin brands like DDAVP?

DDAVP demand is shaped by a mix of epidemiology, clinical practice patterns, and prescribing constraints:

• Chronic disease management: diabetes insipidus often requires long-term treatment
• Pediatric use (nocturnal enuresis): drives sustained volume but increases payer scrutiny and switching sensitivity
• Dose titration: desmopressin dosing can be individualized, keeping patients on a brand/presentation once stabilized
• Treatment standardization: clinician preference and product familiarity can slow switching to newly introduced generics if formulation equivalence is debated in local practice

Financial impact: stable chronic use underpins revenue durability, while cold-chain and adherence factors determine how much of that durability translates into net retention.

---

What does the financial trajectory usually look like for DDAVP-type brands?

DDAVP’s financial trajectory tends to follow a familiar branded pharmaceutical pattern driven by:

1) Patented lifecycle and competition

• Brand revenue typically declines after meaningful generic erosion in key markets.
• “No refrigeration” can delay switching by reducing patient and clinician friction, especially where equivalent products exist but require refrigeration.

2) Pricing and reimbursement dynamics

• Where reimbursement covers chronic desmopressin therapy, stable volumes can persist even as price declines.
• Where reimbursement is restricted, cold-chain simplicity can support formulary access and contract competitiveness.

3) Product mix and formulation-specific switching

Patients may switch within the desmopressin class for tolerability, dosing convenience, and storage needs. A room-stable DDAVP presentation can preserve share by avoiding the practical barriers of refrigerated alternatives.

In financial terms: “no refrigeration” tends to be a share-retention lever more than a top-line growth lever. It can protect margins by preventing accelerated volume loss to lower-priced competitors that carry more burdensome storage.

---

How do market dynamics typically affect revenue and gross margin?

Revenue

Room-stable labeling influences revenue through:

• Lower channel dropout risk (less damaged product, fewer distribution failures)
• Higher refill persistence in chronic care
• More consistent patient access in low-infrastructure settings

This usually supports a gentler volume decline relative to brands requiring refrigeration after generic entrants appear.

Gross margin

Margins improve when:

• Distribution and cold-chain packaging are lower cost
• Handling and returns decrease
• Supply chain complexity drops

However, margins also compress if:

• Buyers use storage advantage to drive price benchmarking against low-cost SKUs
• Tendering bodies favor the lowest-cost room-stable option

Net effect: “no refrigeration” can cushion gross margin deterioration by reducing operational costs and limiting switching, but it does not stop pricing pressure when payer budgets tighten.

---

What investment-grade metrics matter for DDAVP’s financial outlook?

Use these to underwrite DDAVP’s near- to mid-term trajectory:

1. Market share retention by presentation
   Compare share movement between room-stable vs refrigerated competitors at the same dosage strength.

2. Tender performance
   Track contract awards in countries/regions with cold-chain constraints or high last-mile spoilage risk.

3. Net price trend vs volume trend
   “No refrigeration” can preserve volume while price still falls; the key is whether volume erosion slows enough to offset price compression.

4. Prescription persistence
   For chronic indications, measure refill intervals and switch rates between presentations.

5. Supply reliability
   Fewer cold-chain failures often lower service disruptions, which matters in tendered procurement environments.

---

Key takeaways on the “no refrigeration” advantage

1. “No refrigeration” is a channel and adherence lever that reduces operational friction and can protect share after generic entry.
2. The financial trajectory for DDAVP is typically downward on net price over time, but “no refrigeration” can slow the rate of volume loss.
3. Underwriting should prioritize presentation-level share retention, tender outcomes, and persistence metrics, not just headline sales.

---

Key Takeaways

• DDAVP demand is sustained by chronic indications and prescription persistence; “no refrigeration” improves access and adherence mechanics.
• The market impact of room-stable storage is most visible in distribution efficiency, lower switching friction, and tender competitiveness.
• Financial trajectory commonly reflects price compression offset by share retention; room-stable formulations can reduce the speed of volume erosion versus refrigerated presentations.

---

FAQs

1. Does “no refrigeration” increase DDAVP demand, or mainly reduce switching?
   It mainly reduces switching friction and channel dropout risk, supporting persistence and share retention.

2. Which outcomes best demonstrate the “no refrigeration” commercial benefit?
   Presentation-level share retention, tender contract wins, refill persistence, and return-to-shelf or cold-chain incident rates.

3. How does generic competition typically affect DDAVP revenue?
   It usually reduces net price and forces volume share shifts; room-stable storage can slow volume erosion.

4. Is the financial effect driven by patients or wholesalers?
   Both. Wholesalers gain operational simplicity; patients gain easier day-to-day storage, improving adherence and refill continuity.

5. What should be monitored for the next 12 to 36 months?
   Net price trend by market, contract/tender awards for room-stable SKUs, and switch rates between refrigerated and room-stable desmopressin products.

---

References

[1] DDAVP (desmopressin) product information and storage guidance in relevant country labeling.